Connected Diabetes Care: Which Innovations and Growth Opportunities Showcase Vast Potential?
Continuous glucose monitoring (CGM), artificial pancreas systems, and novel insulin delivery formulations to transform the future of diabetes management
Overview
The preference for diabetes self-assessment using wearable CGMs instead of finger-stick blood sugar testing is increasing, especially in type 1 diabetics (T1D). HbA1c (Glycated hemoglobin) and time-in-range are currently the preferred biomarkers for diabetes monitoring applications. Emerging diet and fitness tracking apps help support general well-being and prevent the onset of lifestyle diseases such as diabetes.
How has the use of advanced artificial intelligence (AI) enabled the predictive capabilities of apps, and how can your team capitalize on the same to grow?
Which growth drivers are helping hybrid closed-loop systems and artificial pancreas emerge as a preferred treatment option for optimally managing T1D?
What are the key technological advancements in insulin delivery platforms and innovators across device-based diabetes care platforms driving growth?
Already a member? Click here to access the analysis
Request More Information
Sign up for a complimentary Growth Pipeline Dialog™
A Growth Pipeline Dialog is a structured discussion with our growth experts providing unparalleled technology intelligence and proven implementation best practices. This discussion will spark innovative thinking and help generate a pipeline of growth opportunities you can leverage to maximize your company’s future growth potential.
